News Releases

Printer friendly version

Protox Appoints Dr. Martin Gleave as Chair of Clinical Advisory Board

Vancouver, British Columbia, September 18, 2007 – Protox Therapeutics Inc. (TSX-V:PRX) today announced the appointment of Dr. Martin Gleave MD, FRCSC, FACS, as the Chairman of its Clinical Advisory Board (Urology). Dr. Gleave brings to Protox a wealth of clinical and research experience in the field of prostate disease and will be instrumental in providing strategic guidance as the company advances its clinical programs for both localized prostate cancer and BPH (enlarged prostate).

“Dr. Gleave is an internationally acclaimed researcher, surgeon and urologist and we are extremely pleased tohave attracted a thought leader of his caliber to our Company,” said Dr. Fahar Merchant, President and CEO ofProtox. “Dr. Gleave’s leadership, knowledge and vast clinical experience will be invaluable as we continue to advance the PRX302 clinical programs towards commercialization.”

Dr. Gleave is a Professor in the Department of Urologic Sciences at the University of British Columbia, Director of the Prostate Center at Vancouver General Hospital, Chair of the Genito-Urinary Tumour Group at BC Cancer Agency, and is appointed as a Consultant Urologist for the Department of Urology at the University of Washington. He has published more than 200 peer-reviewed papers, and currently has more that $40M in peer reviewed funding. He is a recipient of many awards, including the National Cancer Institute of Canada’s prestigious William Rawls Award for contributions to cancer control in Canada, Distinguished University Scholar designation by the University of British Columbia, and in 2005, was awarded the BC Leadership Chair in Prostate Cancer Research.

Dr. Gleave is the Founder and CSO of OncoGenex, a private clinical-stage biotechnology company focused on developing new cancer therapies that address treatment resistance in cancer patients. He is active in clinical trials across Canada and is Chairman of the National Cancer Institute of Canada GU Clinical Trials Group, and Chairman of the Canadian Uro-Oncology Group.

About Protox
Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. The company currently has four programs in clinical development based on two distinct but complementary platforms, INxin™ and PORxin™. A Phase 2a clinical trial evaluating PRX321 (INxin) for the treatment of primary brain cancer has been completed and the product candidate has received Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a Phase 1 clinical trial evaluating PRX321 for the treatment of patients with renal cell carcinoma and non-small cell lung cancer has been completed.  Patient enrollment has been completed for a Phase 1 clinical trial evaluating PRX302 (PORxin) for the treatment of localized prostate cancer.  A Phase 1 clinical trial evaluating PRX302 for the treatment of benign prostatic hyperplasia (enlarged prostate) is ongoing.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox’ current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information contact:

James Beesley
Director, Investor Relations
Protox Therapeutics
604-688-0199
jbeesley@protoxtherapeutics.com

Michael Moore
Investor Relations
The Equicom Group
416-815-0700 x 241
mmoore@equicomgroup.com